Context Therapeutics grants 290,000 options to CMO

Context Therapeutics Inc. reported that Chief Medical Officer Karen Deborah Chagin acquired a grant of stock options covering 290,000 shares of the company’s stock.

Rhea-AI Filing Summary

Context Therapeutics Inc. reported that Chief Medical Officer Karen Deborah Chagin acquired a grant of stock options covering 290,000 shares of the company’s stock. The options carry a reported exercise price of $0.0000 per share and are held as direct derivative securities.

According to the vesting terms, 25% of the option award vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, contingent on her continued service with the company.

Insider Trade Summary

Grant/Award: 290,000 shares

Grant/Award 1 txn

Insider Chagin Karen Deborah

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	290,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 290,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CNTX report for Karen Deborah Chagin?

Context Therapeutics reported that Chief Medical Officer Karen Deborah Chagin received a grant of stock options for 290,000 shares. The options are derivative securities with a stated exercise price of $0.0000 per share and are held directly in her name as part of her compensation.

How many stock options were granted to the CNTX Chief Medical Officer?

The Chief Medical Officer of CNTX, Karen Deborah Chagin, was granted stock options covering 290,000 shares. These options represent a right to buy company stock and are structured as a long-term equity incentive, subject to a multi-year vesting schedule tied to continued service.

What is the vesting schedule for Karen Deborah Chagin’s CNTX stock options?

The option grant vests over four years. Twenty-five percent vests and becomes exercisable on February 19, 2027, while the remaining 75% vests in equal monthly installments over the next three years, provided she continues her service with Context Therapeutics during that period.

What is the exercise price of the CNTX stock options granted to the CMO?

The stock options granted to CNTX’s Chief Medical Officer have a reported exercise price of $0.0000 per share. This means she can purchase the underlying shares at that stated price as the options vest and become exercisable according to the four-year vesting schedule.

How many CNTX derivative securities does Karen Deborah Chagin hold after this transaction?

After the reported grant, Karen Deborah Chagin holds 290,000 derivative securities in the form of stock options. This total reflects the newly awarded options and represents her direct beneficial ownership of these option rights following the Form 4 transaction filing by Context Therapeutics.

Is the CNTX option grant to the CMO subject to continued service conditions?

Yes. The option grant to CNTX’s Chief Medical Officer is subject to continued service with the company. Twenty-five percent vests on February 19, 2027, and the remaining options vest in equal monthly installments over three additional years only if her service continues throughout that timeframe.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chagin Karen Deborah

(Last) (First) (Middle)

2001 MARKET ST

SUITE 3915 UNIT #15

(Street)

PHILADELPHIA PA 19103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.32	02/19/2026		A		290,000		(1)	02/18/2036	Common Stock	290,000	$0	290,000	D

Explanation of Responses:

1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.